Work

646. Development of a Novel Chimeric Antigen Receptor as a Therapy Against Solid Tumors

Year: 2016

Type: article

Abstract: The use of chimeric antigen receptor (CAR) T cells as a therapy for cancer is gaining traction as they potentially target tumors with high specificity and minimal off-target toxicities. Current CAR designs consist of an antigen-specific single chain antibody fragment (scFv) fused to the transmembrane and signaling domains of receptors capable of activating T cells. In CAR T cell therapy, patients’ T cells are transduced with cDNA encoding the CAR allowing CAR expressing T cells to target tumor cells.

Source: Molecular Therapy

DOI: 10.1016/s1525-0016(16)33454-2

Authors: John M. Szarejko, Thomas M. Yankee, Gary D. Myers

Institutions: University of Kansas Medical Center, Children's Mercy Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500